Anika Therapeutics (ANIK) Misses Q3 EPS by 1c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.40 -2.35%
Revenue Growth %: +7.0%
Financial Fact:
Income from operations: 13.69M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +7.0%
Financial Fact:
Income from operations: 13.69M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.46, $0.01 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $27.2 million versus the consensus estimate of $28.92 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
- Cintas Corp. (CTAS) Tops Q1 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
